Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

239.34USD
3:35pm EDT
Change (% chg)

$2.01 (+0.85%)
Prev Close
$237.33
Open
$235.34
Day's High
$240.46
Day's Low
$235.15
Volume
345,037
Avg. Vol
1,065,439
52-wk High
$279.65
52-wk Low
$184.58

Latest Key Developments (Source: Significant Developments)

Allergan and Paratek announce positive results from two phase 3 trials of sarecycline
7:31am EDT 

Allergan Plc : Allergan and Paratek announce positive results from two phase 3 trials of sarecycline for the treatment of moderate to severe acne . Allergan Plc - plans to file a new drug application (NDA) to U.S. Food & drug administration (fda) in second half of this year . On track for FDA submission in second half of 2017 .Sarecycline was statistically significantly superior to placebo with respect to primary efficacy endpoints.  Full Article

Allergan and Paratek announce positive results from two phase 3 trials
7:30am EDT 

Paratek Pharmaceuticals Inc : Allergan and Paratek announce positive results from two phase 3 trials of sarecycline for the treatment of moderate to severe acne . Paratek Pharmaceuticals - two phase 3 trials of sarecycline for treatment of moderate to severe acne met their 12 week primary efficacy endpoints .Paratek Pharmaceuticals says Allergan plans to file a new drug application (NDA) to U.S. Food & Drug Administration (FDA) in second half of this year.  Full Article

Allergan reports availability of restasis multidose
Wednesday, 22 Mar 2017 07:31am EDT 

Allergan Plc : Allergan announces availability of restasis multidose™ (cyclosporine ophthalmic emulsion) 0.05 pct -- the first fda-approved preservative free prescription eye drop available in a multidose bottle .Allergan Plc - availability of restasis multidose, which is same preservative-free restasis® formulation, but now offered in a multidose bottle.  Full Article

Juvéderm Vollure XC approved by FDA for correction of facial wrinkles and folds
Monday, 20 Mar 2017 07:31am EDT 

Allergan Plc : Juvéderm Vollure™ XC approved by U.S. FDA for correction of facial wrinkles and folds in adults over the age of 21 .Allergan- Received approval from U.S. FDA to market Juvéderm Vollure XC, for correction of facial wrinkles and folds in adults over age of 21.  Full Article

Allergan and Editas Medicine enter into strategic research and development alliance
Tuesday, 14 Mar 2017 08:00am EDT 

Allergan Plc : Allergan and Editas Medicine enter into strategic research and development alliance to discover and develop Crispr Genome editing medicines for eye diseases . Under terms of agreement, Editas medicine will receive an upfront payment of $90 million for development of five candidate programs . Editas Medicine has potential to earn additional payments for achieving important near-term milestones specifically related to LCA10 . Editas medicine will also be eligible to receive development and commercial milestones, as well as royalty payments on a per-program basis .Allergan will have option to license up to five programs and will be responsible for development and commercialization of optioned products.  Full Article

FDA accepts supplemental new drug application (SNDA) for vraylar
Wednesday, 8 Mar 2017 08:00am EST 

Allergan Plc : FDA accepts supplemental new drug application (SNDA) for vraylar (cariprazine) .Application seeks to expand vraylar label to include Phase 3 clinical data for maintenance treatment of schizophrenia.  Full Article

Zeltiq Aesthetics posts Q4 profit of $0.25/share
Wednesday, 1 Mar 2017 04:17pm EST 

Zeltiq Aesthetics Inc : Zeltiq announces fourth quarter and full year 2016 financial results . Q4 revenue $105.1 million versus i/b/e/s view $102.4 million . Company is no longer providing 2017 financial guidance . Will also not be hosting a Q4 conference call, due to definitive agreement to be acquired by Allergan . Qtrly net income per share $0.25 .Q4 earnings per share view $0.17 -- Thomson Reuters I/B/E/S.  Full Article

Allergan agrees to acquire Zeltiq for $2.48 bln
Monday, 13 Feb 2017 08:00am EST 

Allergan Plc : Allergan has agreed to acquire Zeltiq for $56.50 per share, or $2.475 billion . Deal for for $56.50 per share . Allergan to acquire Zeltiq, best-in-class company in fast-growing body contouring segment, for $2.47 billion . Acquisition of Zeltiq is immediately accretive .Moelis & Company is acting as financial advisor to Allergan, and Debevoise & Plimpton LLP is acting as lead legal counsel.  Full Article

Allergan says does not see U.S. tax reform in 2017
Wednesday, 8 Feb 2017 09:49am EST 

Allergan Plc - : Allergan CEO "We have a good report card for 2016 and a positive outlook for 2017 and beyond" . Allergan CEO "We are optimistic that the new administration is pro-growth, pro-innovation and against overregulation that could stifle investment & growth" . Allergan CEO says is pleased to see number of peers are following the Co's lead & becoming vocal about actions they are taking to price products responsibly . Allergan chief commercial officer says is pleased with performance of viberzi; says "it looks and feels just like linzess" . Allergan CEO says "We are engaged with the new administrationand certainly the key folks within congress" . Allergan CEO: "There's no real plan yet for what tax reform will look like nor when it will appear" . Allergan CEO: "something that could be detrimental or have a negative effect could be a border adjustment" . Allergan exec says "In August, we will evaluate whether to sell Teva stock" . Allergan exec says expected U.S. Tax reform does not change co's view on capital deployment, specifically for 2017 . Allergan CEO "i don't think we will see tax reform in 2017" . Allergan says could see some volume erosion for restatis with some modest price appreciation in 2017 or, the reverse, depending on formulary coverage . Allergan: in Q4 there were no surprises with restasis, no major swings in wholesaler buying patterns; growth was driven by a solid mix of volume & price.  Full Article

Allergan declares first quarterly cash dividend of $0.70 per ordinary share
Friday, 3 Feb 2017 08:04am EST 

Allergan Plc - :Allergan declares first quarterly cash dividend of $0.70 per ordinary share.  Full Article

More From Around the Web

Impax Labs names industry veteran Paul Bisaro as CEO, shares soar

Impax Laboratories Inc, which is said to be conducting a strategic review, named former Allergan Plc executive and industry veteran Paul Bisaro as its chief executive, sending the drugmaker's shares soaring as much as 38 percent.